Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report, 2023 Updates, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Relapsed/Refractory Acute Myeloid Leukemia pipeline constitutes 50+ key companies continuously working towards developing 50+ Relapsed/Refractory Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Relapsed/Refractory Acute Myeloid Leukemia Overview
Relapsed/Refractory Acute Myeloid Leukemia which means the leukemia has come back after treatment and remission. RefractoryAML means the leukemia did not respond to treatment. AML relapse affects about 50% of all patients who achieved remission afterinitial treatment, and can occur several months to several years after treatment.

“Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Relapsed/Refractory Acute Myeloid Leukemia Market.

The Relapsed/Refractory Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report:
• Companies across the globe are diligently working toward developing novel Relapsed/Refractory Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years. Relapsed/Refractory Acute Myeloid Leukemia Key players such as – Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics, AROG Pharmaceutical, and others, are developing therapies for the Relapsed/Refractory Acute Myeloid Leukemia treatment
• Relapsed/Refractory Acute Myeloid Leukemia Emerging therapies such as – CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others are expected to have a significant impact on the Relapsed/Refractory Acute Myeloid Leukemia market in the coming years.
• In January 2021 Apollomics and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).

Route of Administration
Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Product Type
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Product Type
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia By Stage and Route of Administration
• Relapsed/Refractory Acute Myeloid Leukemia Assessment by Molecule Type
• Relapsed/Refractory Acute Myeloid Leukemia by Stage and Molecule Type

DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Relapsed/Refractory Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:
• APG-2575: Ascentage Pharma
• CLN 049: Cullinan Oncology
• Lanraplenib: Kronos Bio
• CYAD-02: Celyad Oncology
• FHD-286: Foghorn Therapeutics
• AB8939: AB Science
• ONC201: Oncoceutics
• Sarclisa: Sanofi
• TCB008: TC Biopharm
• Keytruda: Merck & Co
• Uproleselan: GlycoMimetics
• Crenolanib: AROG Pharmaceuticals

Get a Free Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutic Assessment

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis:
The Relapsed/Refractory Acute Myeloid Leukemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Relapsed/Refractory Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsed/Refractory Acute Myeloid Leukemia Treatment.
• Relapsed/Refractory Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsed/Refractory Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsed/Refractory Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Relapsed/Refractory Acute Myeloid Leukemia product details are provided in the report. Download the Relapsed/Refractory Acute Myeloid Leukemia pipeline report to learn more about the emerging Relapsed/Refractory Acute Myeloid Leukemia therapies

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Drivers
• Rising incidence of Acute Myeloid Leukemia
• Advancements in pharmacology and molecular biology to promote drug development
• Rising geriatric population

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Market Barriers
• High cost associated with the management of AML
• Side effects associated with the AML treatment

Scope of Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drug Insight
• Coverage: Global
• Key Relapsed/Refractory Acute Myeloid Leukemia Companies: Celyad Oncology, Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics, AROG Pharmaceutical, and others
• Key Relapsed/Refractory Acute Myeloid Leukemia Therapies: CYAD-02, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment: Relapsed/Refractory Acute Myeloid Leukemia current marketed and Relapsed/Refractory Acute Myeloid Leukemia emerging therapies
• Relapsed/Refractory Acute Myeloid Leukemia Market Dynamics: Relapsed/Refractory Acute Myeloid Leukemia market drivers and Relapsed/Refractory Acute Myeloid Leukemia market barriers

Request for Sample PDF Report for Relapsed/Refractory Acute Myeloid Leukemia Pipeline Assessment and clinical trials

Table of Contents
1 Relapsed/Refractory Acute Myeloid Leukemia Report Introduction
2 Relapsed/Refractory Acute Myeloid Leukemia Executive Summary
3 Relapsed/Refractory Acute Myeloid Leukemia Overview
4 Relapsed/Refractory Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment
5 Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics
6 Relapsed/Refractory Acute Myeloid Leukemia Late Stage Products (Phase II/III)
7 Relapsed/Refractory Acute Myeloid Leukemia Mid Stage Products (Phase II)
8 Relapsed/Refractory Acute Myeloid Leukemia Early Stage Products (Phase I)
9 Relapsed/Refractory Acute Myeloid Leukemia Preclinical Stage Products
10 Relapsed/Refractory Acute Myeloid Leukemia Therapeutics Assessment
11 Relapsed/Refractory Acute Myeloid Leukemia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Relapsed/Refractory Acute Myeloid Leukemia Key Companies
14 Relapsed/Refractory Acute Myeloid Leukemia Key Products
15 Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs
16 Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers
17 Relapsed/Refractory Acute Myeloid Leukemia Future Perspectives and Conclusion
18 Relapsed/Refractory Acute Myeloid Leukemia Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Relapsed/Refractory Acute Myeloid Leukemia drugs and therapies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting